Neeraj Songara: Shelf-Stable Synthetic Blood – The Future of Emergency Transfusion?
Neeraj Songara, Resident Doctor at Dr S.N. Medical College Jodhpur, shared a post on LinkedIn:
“Shelf-Stable Synthetic Blood: The Future of Emergency Transfusion?
A promising advancement in transfusion medicine is bringing freeze-dried, shelf-stable synthetic blood closer to human trials.
Kalocyte, in collaboration with the University of Maryland, Baltimore, is developing this technology with support from DARPA.
Why does it matter?
Conventional RBCs require 1–6°C storage and a continuous cold chain—limiting blood availability in:
- Battlefield and military medicine
- Prehospital trauma care
- Rural/remote emergencies
- Disaster and mass-casualty situations
- Air evacuation and austere environments
A new approach to artificial blood
Earlier hemoglobin-based oxygen carriers faced major safety concerns because free hemoglobin can cause vasoconstriction, inflammation and organ injury.
Kalocyte’s approach aims to create synthetic microscopic cells that mimic key RBC functions, including:
- Oxygen delivery
- Hemodynamic support
- Appropriate blood-flow properties
- Hemostatic function
- Minimal immune/thrombotic reactions
- Potential ABO-independent use
The game-changing feature
The product is being developed as a freeze-dried powder designed for prolonged room-temperature storage and rapid reconstitution when required.
Freeze-dried – store at room temperature – reconstitute – transfuse
This could bring blood-substitute technology directly to the point of injury rather than requiring a refrigerated blood supply.
Potential applications
- Battlefield
- Ambulances
- Disaster zones
- Remote healthcare
- Mass casualties
- Extreme environments
Current status
This remains an investigational technology. Human trials and rigorous evaluation of oxygen delivery, hemostasis, immunogenicity, thrombosis, organ safety and clinical outcomes are still essential.
The goal is not necessarily to replace donor blood, but to bridge the critical gap between hemorrhage and definitive medical care.
From cold-chain-dependent donor blood toward rapidly deployable, shelf-stable blood substitutes.
A potentially transformative development for Transfusion Medicine and emergency care.”
Stay updated with Hemostasis Today.
-
Aug 22, 2026, 13:38Jerome Hadjadj: A New Approach to Refractory Immune Thrombocytopenia
-
Aug 22, 2026, 13:25Christopher Robinson: Hematologic Response to Iron Therapy and Stillbirth Risk
-
Aug 22, 2026, 13:24Philippa Hill: Blood Clot Awareness – Recognize the Signs, Prevent the Risk
-
Aug 22, 2026, 13:21Chokri Ben Lamine: ASH 2026 Adult Primary ITP Guidelines – Practice-Changing Update
-
Aug 22, 2026, 13:07Saneha Anjum Shaikh: Blood Bank Basics and Quality Control in Automation
-
Aug 22, 2026, 11:36Bernardo Gindri: How platelets Influence Cancer Progression
-
Aug 22, 2026, 11:34Nick Gehrig: Extending Platelet Shelf Life to Strengthen Blood Supply
-
Aug 22, 2026, 11:14Lei Yu: New Guidance for Acute Pulmonary Embolism in 2026
-
Aug 22, 2026, 10:41Mike R.։ VTE Thrombectomy – Defining What Success Really Means